Alnylam Pharmaceuticals Inc
ALNY · Health Technology · Biotechnology · US
2,500 employees · alnylam.com
About
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts.
Annual results
Reported figures, USD · revenue up 65.2% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 3.7B | 313M | 8.4% | — |
| 2024 | 2.2B | -278M | -12.4% | — |
| 2023 | 1.8B | -440M | -24.1% | — |
| 2022 | 1.0B | -1.1B | -109.1% | — |
| 2021 | 844M | -852M | -100.9% | — |
ALNY in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Alnylam Pharmaceuticals Inc are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.